BrainChip’s Reset: Missed Milestones and a Revised Path Forward

BrainChip Holdings Ltd. has confirmed the lapse of a significant number of equity-linked incentives, casting a spotlight on the company’s recent operational performance. More than 7.4 million performance rights, options, and restricted stock units (RSUs) expired after the associated performance and service conditions were not met by the February 28, 2026 deadline. The formal announcement was made to the market on April 2.

A Reduction in Potential Dilution

The expiration of these 7,422,060 instruments results in a minor but positive technical outcome for current shareholders: it slightly reduces the potential future dilution of their holdings, as these shares will not now be issued. The total number of shares already outstanding remains unchanged.

However, the underlying reason for the lapse sends a more concerning signal. It indicates that specific operational or financial targets set for the relevant period were not achieved. For a company under pressure to demonstrate commercial traction, this development is an unwelcome marker of the challenges in translating technological ambition into tangible business results.

Index Removal and a Dual-Chip Strategy

The context for this news was further shaped by an earlier event. On March 23, 2026, BrainChip was removed from the S&P/ASX 300 Index as part of a routine quarterly rebalancing. Such exclusions typically diminish a stock’s visibility and can reduce demand from institutional funds that track the index.

Should investors sell immediately? Or is it worth buying BrainChip?

In response to these headwinds, the company is pivoting attention to its forthcoming technical roadmap. The focal point is the anticipated arrival of first production silicon for its AKD1500 processor, scheduled for the third quarter of 2026.

Running in parallel is the development of the AKD2500, a custom silicon project with an allocated budget of approximately $2.5 million. This chip is designed to implement the Akida 2.0 architecture using a 12-nanometer process technology. Prototypes of the AKD2500 are also slated to be available for customer testing in Q3 2026.

The critical question for the remainder of the year is whether these impending technical milestones will finally catalyze the substantial royalty revenues that recent licensing agreements have promised. The company’s ability to bridge the gap between its advanced neuromorphic computing technology and sustained financial performance remains the paramount challenge for investors.